医学
痹症科
耐火材料(行星科学)
队列
跨国公司
内科学
亚太地区
家庭医学
物理疗法
政治学
业务
天体生物学
物理
国际贸易
法学
作者
Rangi Kandane‐Rathnayake,Worawit Louthrenoo,Chak Sing Lau,Laniyati Hamijoyo,Jiacai Cho,Aisha Lateef,Shue‐Fen Luo,Yeong‐Jian Jan Wu,Sandra Navarra,Leonid D. Zamora,Zhanguo Li,Yi‐Hsing Chen,Shereen Oon,Madelynn Tsu-Li Chan,Sargunan Sockalingam,Yanjie Hao,Zhuoli Zhang,Sang‐Cheol Bae,Jun Kikuchi,Tsutomu Takeuchi
标识
DOI:10.1186/s13075-025-03622-8
摘要
BACKGROUND: Emerging therapies have the potential to be used in patients with severe refractory systemic lupus erythematosus (srSLE), but no agreed definition of srSLE exists. We evaluated a pilot srSLE definition to assess whether a set of disease activity and treatment thresholds could identify patients with poor outcomes. METHODS: Data from a 13-country longitudinal SLE cohort, collected prospectively between 2013 and 2020 were analysed. srSLE was defined if a patient was in high disease activity (SLEDAI-2K ≥ 10) despite combination use of at least glucocorticoids (GC) and immunosuppressants (IS) at both the index and preceding visit. Synchronised to the index srSLE visit, we assessed disease activity, medication use and treat-to-target (T2T) endpoint attainment over 12 months (m). RESULTS: Of 3,744 patients studied, 578 (14%) had srSLE, in 1,810 visits. The median [IQR] SLEDAI-2K at the srSLE index visit was 12 [10, 14], which decreased to 6 [4, 10] at 6m and 12m. Most patients remained on combination anti-malarial, GC, and IS at all follow-up time points. The median [IQR] GC dose at the index visit was 10 [5, 20] mg/day; this reduced to 8 mg [5.0, 12.9] at 6m and 5 mg [5.0, 10.0] at 12m. Less than a quarter of patients attained LLDAS and only 1% attained GC-free remission over 12 months. CONCLUSIONS: A draft definition of srSLE was clearly associated with poor outcomes. Work to evaluate multiple thresholds with which to define srSLE, and their outcomes, is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI